Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome
作者: K. ImaiY. EmiK.-I. IyamaT. BeppuY. OgataY. KakejiH. SamuraE. OkiY. AkagiY. MaeharaH. Baba
作者单位: 1Department of Gastroenterological Surgery, Graduate School of Life Sciences, Kumamoto University, Kumamoto, Japan
2Department of Surgery and Science, Graduate School of Medical Science, Kyushu University, Fukuoka, Japan
3Department of Surgical Pathology, Kumamoto University Hospital, Kumamoto, Japan
4Department of Surgery, Kurume University Medical Center, Kurume, Japan
5Department of Surgery, Division of Gastrointestinal Surgery, Graduate School of Medicine, Kobe University, Kobe, Japan
6Division of Digestive and General Surgery, Faculty of Medicine, University of the Ryukyus, Okinawa, Japan
7Department of Surgery, Kurume University Hospital, Kurume, Japan
刊名: European Journal of Surgical Oncology, 2014, Vol.40 (5), pp.559-566
来源数据库: Elsevier Journal
DOI: 10.1016/j.ejso.2013.12.009
关键词: Sinusoidal obstruction syndromeColorectal liver metastasesBevacizumabOxaliplatinSplenic volume
英文摘要: Abstract(#br)Aims(#br)The aim of this study was to investigate the relationship between the use of bevacizumab (Bmab) in addition to oxaliplatin (OX), the development of sinusoidal obstruction syndrome (SOS) and the changes in splenic volume as an indicator of the protective effect of Bmab against OX-induced SOS.(#br)Methods(#br)Seventy-nine patients who received OX-based chemotherapy with (OX + Bmab group: n = 48) or without Bmab (OX group: n = 31) for colorectal liver metastases were included in this study. The changes in splenic volume after chemotherapy were evaluated in the two groups. Furthermore, the relationship between the changes in splenic volume and SOS were analyzed in the 55 patients who underwent hepatectomy.(#br)Results(#br)A significant increase in the splenic volume was...
全文获取路径: Elsevier  (合作)
分享到:
来源刊物:
影响因子:2.614 (2012)

×